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Abstract |  
Genomic imprinting, the monoallelic and parent-of-origin-dependent expression of a 
subset of genes, is required for normal development. Its disruption leads to human 
disease involving isolated or multi-locus epigenetic changes that can be traced back 
to alterations of cis-acting sequences or trans-acting factors controlling the 
establishment, maintenance and erasure of germline epigenetic imprints or may 
have no evident genetic cause. Recent insights into the dynamics of the epigenome 
including the effect of environmental factors suggest that the developmental 
outcomes and heritability of imprinting disorders are influenced by interactions 
between the genome, the epigenome and the environment in germ cells and early 
embryos. In this Review, we discuss the latest advances in the study of genomic 
imprinting, focusing on the imprinting life-cycle and its possible errors leading to 
human diseases. We discuss the modes of inheritance of imprinting defects and 
 2
evidences from humans and animal models that environmental factors may influence 
genomic imprinting. Finally, we highlight areas requiring additional research that 
could complete our understanding of imprinting disorders, as well as new 





In therian mammals, a subset of autosomal genes is preferentially expressed from 
only one of the two parental chromosomes, some from the maternally inherited 
allele, others from the paternal allele1. This parental origin-dependent expression 
results from differential epigenetic marking, primarily from methylated cytosine at 
CpG dinucleotides of genes during gametogenesis in the male and female germline. 
These genomic imprints endure for one generation, from their establishment in 
mature germ cells of an individual to their erasure in the gamete precursors of their 
progeny. Genomic imprinting thus represents a type of intergenerational epigenetic 
inheritance. Of note, parent-of-origin-dependent methylation differs from sequence-
dependent allelic methylation, in which stochastic fluctuation between epialleles [G] 
is influenced by genetic variants2.  
In humans, approximately 100 imprinted genes have been identified 3-5. Many 
imprinted genes have important roles during human development, and alteration of 
their expression and function can lead to imprinting disorders (Table 1), congenital 
conditions with a lifelong impact on health and in some cases increased cancer risk6.  
Molecular changes underlying imprinting disorders comprise genetic changes, such 
as copy number variants (CNVs), uniparental disomy [G] (UPD), and pathogenic 
gene sequence variants, or epigenetic changes that affect the regulation of imprinted 
loci (epimutations [G]). The frequency of the four types of molecular alterations 
varies markedly between different imprinting disorders, with the highest frequency of 
epimutations in the chromosome 11p15-associated disorders Beckwith–Wiedemann 
syndrome (BWS) and Silver–Russell syndrome (SRS)7. Epimutations that occur 
without detectable DNA sequence changes are referred to as primary epimutations 
and may represent random or environment-driven errors in the establishment or 
maintenance of an epigenetic programme. By contrast, secondary epimutations arise 
downstream from genetic changes that affect cis-acting elements or trans-acting 
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factors8. As normal imprinting marks once set persist throughout the life course of an 
organism, similarly, imprinting errors originating in the germline as primary or 
secondary epimutations are permanently maintained in somatic tissues, resulting in 
disease phenotypes later in development. Primary or secondary epimutations (as well 
as UPDs) that occur after fertilization can result in somatic mosaicism (Box 1). 
Although genetic alterations and epimutations differ in their nature and aetiology, 
they all disturb the fine-tuned balance of imprinted gene expression. In some cases, 
loss of methylation (LOM) and gain of methylation (GOM) of the same imprinting 
centre result in ‘mirror’ disorders that are broadly characterized by opposite clinical 
features and gene expression patterns, for example, in the case of BWS and SRS 
(Table 1 and Fig. 1)7. 
Advances in whole-genome sequencing and single-cell genome-wide analysis are 
driving the study of imprinting disorders arising from pathogenic variants that disrupt 
key epigenetic reprogramming processes in early embryogenesis, shedding new 
light on the dynamics of the epigenome as it passes from parents, through gametes, 
to offspring. Furthermore, recent studies on the interaction between environment and 
the epigenomes of gametes and early embryos suggest mechanistic explanations for 
the sporadic occurrence of imprinting errors.  
This Review focuses on imprints that effect essentially permanent and ubiquitous 
(rather than tissue-specific or transient (Box 2)) changes on gene expression 
potential at affected loci. We begin with a brief overview of the genomic basis of 
imprinting and its control, before reviewing the lifecycle of genomic imprinting and 
how disruption of the individual factors involved in the establishment, maintenance 
and erasure of imprints can result in disease. Finally, we discuss the heritability of 
imprinting defects and the role of environmental insults in imprinting disorders. For 
details on the evolutionary significance of genomic imprinting1,9, the methods for 
imprinting analysis10, the physiological role of imprinted genes6 or the chromatin 
mechanisms in imprinting11, the reader is referred to previous authoritative reviews. 
 
[H1] The genomic basis of imprinting 
The majority of imprinted genes are found in clusters, called imprinted domains, 
which enables coordination via shared regulatory elements such as long non-coding 
RNAs (lncRNAs) and differentially methylated regions (DMRs), where DNA 
methylation differs between the maternally derived and paternally derived alleles. 
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Each imprinted domain is controlled by an independent ‘imprinting centre’, which is 
generally characterized by a germline differentially methylated region (gDMR), also 
known as primary DMR (Fig. 2). About 35 gDMRs associated with imprinted loci 
have been identified in the human genome (Table 2)12. gDMRs are also 
characterized by different chromatin configurations on parental chromosomes, with 
histone marks characteristic of closed chromatin (for example, histone 3 lysine 9 
dimethylation (H3K9me2), trimethylation (H3K9me3) and histone 4 lysine 20 
trimethylation (H4K20me3)) on the methylated allele, and histone marks 
characteristic of open chromatin (for example, H3K4me2 and H3K4me3) on the 
unmethylated allele (Fig. 2)4,11,13. The methylated and unmethylated gDMR alleles 
are recognized by different transcription factors whose function is to direct differential 
epigenetic modification and imprinted expression of the locus (Fig. 2)14. Whereas 
maternally methylated gDMRs are more numerous, intragenic and generally 
correspond to promoters, often of lncRNAs, gDMRs methylated on the paternal 
chromosomes are intergenic and may function as insulators or enhancers (Table 
2)1,15. Of note, in multigenic imprinted domains, the imprinting centre often directs the 
expression of genes from both the chromosome on which is methylated and the 
opposite parental chromosome; this situation arises from the regulatory interactions 
between imprinting centres and the gene products, both coding and noncoding, 
under their control (Fig. 2). 
 
[H2] Allele-specific expression in somatic cells  
Imprinted genes can display monoallelic expression in most or all cell types, but for 
some genes imprinted expression is restricted to specific tissues (for example, 
UBE3A16,17) or developmental windows (for example, KCNQ118), or monoallelic 
expression and/or methylation can differ between individuals19-21. To control the 
allele-specific expression of imprinted genes in somatic cells, gDMRs direct the 
establishment of further allele-specific epigenetic features within the imprinted 
domain during development. These include secondary DMRs (also known as 
somatic DMRs), which correspond mostly to gene promoters and transcription factor 
binding sites (Table 2)20, chromatin modifications and higher-order chromatin 
structures (possibly resulting from CTCF–cohesin interactions)22,23, and lncRNAs 
with silencing capacity for flanking imprinted genes in cis24 (Figs 1, 2a) (reviewed in 
REF. 1). In other cases, imprinted gDMRs direct alternative splicing, transcription 
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elongation or polyadenylation site usage, which results in allele-specific transcript 
isoforms20,25. A minority of genes with parent of origin-dependent expression in 
somatic tissues have no evident DMR in their vicinity20, and their allele-specific 
expression may possibly be controlled by epigenetic features other than DNA 
methylation26.  
Tandem repeats are a prominent feature of imprinting centres27. Some repeats 
function to concentrate a high density of binding sites for transcription factors that 
regulate imprinted gene expression; for example, the tandem repeats in the H19-
IGF2 IG-DMR concentrate methylation restricted binding of ZFP57 and CTCF that 
are critical for imprinting (Fig. 2)28,29. In this case, their recombination results in 
recurrent imprinting defects30. On the other hand, deletion of a large array of repeats 
of long-interspersed elements (LINE-1) in the Dlk1–Dio3 imprinting domain in mouse 
embryonic stem (ES) cells did not disrupt imprinting, or, apparently normal 
development of both maternal and paternal mutant mice31, which does not support a 
role for these repeats in imprinting.  
Imprinted gene products intensify their exquisite regulation by co-operation in a 
network (Imprinted gene network, IGN)32,33. For example, the transcription factor 
PLAGL132 and the H19 lncRNA33 have been shown to regulate the mRNA level of 
several members of the IGN in a DNA methylation-independent manner, in mouse 
tissues. The human lncRNA IPW, which resides within the Prader–Willi syndrome 
(PWS) locus on chromosome 15, is able to regulate the expression of MEG3 on 
chromosome 14 by targeting the EHMT2 H3K9 histone methyltransferase (also 
known as G9a) to its imprinting centre34. Furthermore, many imprinted gene clusters 
encode microRNAs (miRNAs) and small nucleolar RNAs (snoRNAs), which may be 
involved in the post-transcriptional control of imprinted genes35. These interactions 
may explain some of the overlaps observed in the phenotypes of imprinting disorders 
(Table 1). 
 
[H2] Multilocus imprinting disturbances  
A subset of patients with imprinting defects exhibits multilocus imprinting 
disturbances (MLID), that is, imprinting disruption at multiple loci across the genome. 
MLID is confined to epimutation subgroups of imprinting disorders (Table 1) and 
involves loci associated with known imprinting disorders as well as those not 
currently linked with specific phenotypes36,37. To date, most patients with MLID have 
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shown clinical features characteristic of one imprinting disorder, notably BWS, SRS 
or transient neonatal diabetes mellitus (TNDM), which is probably due to the high 
frequency of epimutations in these imprinting disorders. However, epigenotype–
phenotype correlations are not always obvious, possibly because of the spectrum of 
epimutations involved or their mosaic nature (Box 1)37-39.  
 
 
[H1] The imprinting life-cycle and disease  
Throughout their generational lifespan (Fig. 3), genomic imprints must be maintained 
and preserved from epigenetic reprogramming in somatic cells. Many factors 
involved in these complex processes and their DNA binding sites can be targets of 
mutations that cause human imprinting disorders (Table 3). 
 
[H2] Imprinting centre methylation dynamics in germ cells 
Of the ubiquitous gDMRs present in somatic tissues, all but two originate from the 
oocyte (Table 2)5,12. This disparity reflects fundamental differences in the 
mechanisms of methylation acquisition in the female and male germlines, and in the 
treatment of parent-of-origin-derived methylation in the zygote (Fig. 3)21. In primordial 
germ cells (PGCs), the precursors of sperm and oocytes, germline specification 
requires remodelling of the epigenome as a pre-requisite for gametogenesis. Our 
knowledge of these processes comes chiefly from studies in mice40,41, and the 
characterization of human PGCs has revealed subtle interspecies differences, but 
overall the global erasure of methylation is comparable42-44.  
A hallmark of PGC remodelling is imprint erasure. Genome-wide de-methylation of 5-
methylcytosine (5mC) is a passive process during PGC expansion that results from 
diminished protein levels of the de novo DNA methyltransferase DNMT3A and 
UHRF1, the recruitment factor of the maintenance DNA methyltransferase DNMT1. 
Reprogramming of imprinted methylation follows slower kinetics. In mice, it is 
associated with oxidation of 5mC to 5-hydroxymethylcytosine (5hmC) by the ten-
eleven translocation 5mC dioxygenase 1 (TET1) and TET2; this modification is not 
recognized by the maintenance methylation machinery and therefore promotes 
passive demethylation40,41,44,45.  
Errors in the erasure process have been observed in patients with rare, sporadic 
imprinting disorders. In the case of GOM of the PWS/AS imprinting centre (also 
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known as SNURF:TSS-DMR), grandmaternal methylation is not erased in paternal 
PGCs, and as a result the paternal allele retains this maternal imprint (Fig. 4a)46. 
Similarly, the hypermethylation of imprinting centres in sperm from subfertile 
individuals is consistent with incomplete erasure of imprints47.  
Re-methylation and imprint acquisition occur asynchronously between the sexes, 
with de novo methylation in the male germline occurring before birth and maintained 
through many cycles of mitotic division before entry into meiosis, whilst female germ 
cells remain hypomethylated until maturation (Fig. 3). De novo methylation and 
imprint acquisition initiate in meiotically arrested (at prophase I) mouse oocytes 
following birth, and are largely completed by the germinal vesicle stage of 
development and resumption of meiosis42,48-51. Such dynamics have not been 
extensively studied in human oocytes52; however, in humans, meiosis II oocytes and 
the first and second polar bodies have comparable methylation, including at 
imprinted maternally methylated gDMRs49 (D. M., unpublished observations), which 
suggests the timings are similar to mouse. 
On the basis of data derived from mouse models, the majority of methylation is 
deposited in oocytes by DNMT3A and its obligate, catalytically inert, cofactor 
DNMT3L51,53,54, whereas both DNMT3A and DNMT3B contribute in male germ 
cells55. DNMT1 has an auxiliary role ensuring symmetric methylation of CpG sites in 
oocytes56. Transcription and underlying chromatin signature are important factors 
determining methylation acquisition50. Transcription in oocytes is required for 
methylation at numerous gDMRs57, an act that may render the chromatin more 
accessible to the de novo methylation machinery and/or be associated with specific 
chromatin changes. The co-transcriptional histone H3K36me3 mark is deposited at 
intragenic CpG islands and subsequently recognized by DNMT3A and DNMT3B58,59. 
Successive removal of dimethylation and trimethylation of histone H3K4 by KDM1A 
or KDM1B (known previously as AOF1 and LSD1, respectively) allows for direct 
interaction with DNMT3L60-62. Despite being a generic methylase in mouse oocytes, 
DNMT3L is not detectable by expression profiling in human oocytes between 
germinal vesicle phase and meiosis II63, suggesting that it is not required for de novo 
methylation in the human female germline. In mouse male germ cells, transcriptional 
read-through is involved in acquisition of imprinting centre methylation, whereas 
histone H3K4 methylation and promoter activity are present at maternal imprinting 
centres that are protected from de novo methylation64.  
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Failure to establish imprints during gametogenesis can result in imprinting disorders. 
Establishment of gDMRs involves several enzymatic steps, any of which may be 
prone to stochastic errors. In oocytes, deficient transcription through CpG islands 
destined to be gDMRs can result in failure to establish maternal imprints57; in such 
cases, there would be no mosaicism (Fig. 4b)65. Genetic mutations affecting 
transcription through the gDMR have been identified in rare patients with BWS with 
complete and isolated lack of methylation at the imprinting centre 2 (IC2), the 
imprinting centre of the centromeric domain of the BWS/SRS locus (also known as 
KCNQ1OT1:TSS-DMR) (REF66 and A. R., unpublished observations), and disruption 
of germline transcription is probably also present in Angelman Syndrome (AS) cases 
with non-mosaic LOM of the SNURF:TSS-DMR and deletions of the AS smallest 
region of deletion overlap (AS-SRO)67.  
 
[H2] Imprinting centre methylation dynamics in the early embryo 
The divergent DNA methylation patterns of oocyte and sperm are harmonized by the 
time the embryo reaches the blastocyst stage51,68, as part of the extensive epigenetic 
reprogramming that underpins zygotic genome activation [G] (ZGA; Box 3 and 
reviewed in REF69) and is required first to acquire totipotency and subsequently to 
initiate differentiation. The murine paternal genome is demethylated early in the first 
cell cycle, in part by TET3-induced oxidation of 5mC5,49,68,70, whereas maternal 
demethylation is predominantly passive, by replicative dilution during cleavage-stage 
divisions, possibly through the restricted activity or localization of DNMT1 and its 
accessory factors (Fig. 3)71,72. Studies in human systems are currently limited but 
indicate differences in abundance and roles of DNMTs in the oocyte and embryo63. 
However, in both humans and mice, whereas most gDMRs lose DNA methylation in 
pre-implantation stages49,51, imprinting centres evade the embryonic wave of 
epigenetic reprogramming, and studies in both mouse models and human patients 
with rare imprinting disorders suggest they do so through interaction with critical 
factors expressed in the oocyte and early embryo.  
 
[H2] Oocyte factors 
DPPA3 (also known as Stella or PGC7) is required for the maintenance of DNA 
methylation in the early mouse embryo and protects 5mC from conversion to 5hmC 
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in the maternal pronucleus, by associating with chromatin marked by H3K9me273. 
DPPA3 is a maternal-effect gene: concepti of maternal null mice rarely progress 
beyond the two-cell stage, and their genomes are severely demethylated74. 
Maternal-effect variants in NLRP proteins and associated factors have been 
implicated in pregnancy outcomes including hydatidiform mole [G] and infertility, as 
well as monozygotic twinning, pregnancy loss and MLID (Fig. 4c-d)37,39,75,76. Women 
with biallelic inactivating NLRP7 mutations are affected by familial hydatidiform mole 
(FHM)77, where nonviable products of conception have normal biparental genomic 
constitution but complete loss of maternal imprinting marks. The high penetrance [G] 
of FHM suggests that NLRP7 is involved in oocyte-specific imprint establishment 
(Fig. 4c)78, but hypomorphic maternal NLRP7 variants have been associated with 
MLID79.  
In mouse models, NLRP5 and its associated proteins are referred to as the 
subcortical maternal complex (SCMC)80. They are highly expressed in the oocyte, 
but their mRNA and protein abundance decline to undetectable levels by 
blastulation81. In mouse models, maternal ablation of SCMC gene function 
compromises embryo development, with frequent demise between the 2-cell and 
blastula stage, and disruption of processes including maintenance of genome 
integrity, euploidy, mitochondrial function, and gene transcription and translation82-84. 
A mouse model of maternal Nlrp2 deficiency shows severe reproductive compromise 
with embryo demise at all developmental stages and mosaic loss and gain of 
methylation at imprinted loci, indicating that abnormal subcellular localization of 
DNMT1 and or SCMC members may cause early embryonic loss and imprinting 
defects85.  
The effects of maternal SCMC variants suggest a link between DNA methylation, 
genome integrity and developmental competence in the early embryo. If the 
embryo’s competence is severely compromised, both ploidy and DNA methylation 
may be intolerably affected, leading to embryo demise. If errors in ploidy and/or 
methylation are tolerated, the embryo may survive blastulation and continue 
development, with ongoing differentiation overwriting early epigenetic errors — 
except for imprints, which are indelible in somatic cells. Evidence for this comes from 
reports of preimplantation genetic diagnosis of embryos with maternal-effect NLRP7 
mutations in which all cleavage-stage embryos arrested and had various maternal 
aneuploidies86. Arguably, if an embryo had presented with a normal chromosome 
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complement it would have likely developed into a molar pregnancy or severe MLID 
due to disturbed maternal imprints. Hence, MLID may be no more or less than 
evidence of embryonic crises during the critical window encompassing epigenetic 
reprogramming and ZGA, with an ascertainment bias for live birth and normal ploidy.  
Mothers with maternal-effect variants have children with variable disturbance of both 
paternally- and maternally-methylated imprinting centres (Fig. 4d), and a spectrum of 
reproductive outcomes including apparent infertility, fetal loss, hydatidiform mole, 
liveborn children with MLID who exhibit clinical symptoms, and liveborn children with 
MLID and no clinical phenotypes37,39. The only consistent feature of offspring is MLID 
itself.  
 
[H2] Zygotic factors 
The KRAB zinc-finger protein (KRAB ZFP) ZFP57 acts as the focus for a multi-
protein complex that protects imprinting centres from both passive and active 
demethylation87-89. ZFP57 recognizes a hexameric motif enriched in all maternally 
and paternally methylated imprinting centres in mouse90,91. KRAB ZFPs are a large, 
expanding family; their rapid evolution seems to keep pace with the endogenous 
retroviruses (ERVs) whose expression they suppress through DNA 
hypermethylation92. Besides repressing retroviral transcription, ZFP57 protects DNA 
methylation of imprinted loci in early development. In mice, Zfp57 is a maternal-
zygotic-effect gene the ablation of which is incompatible with full offspring survival87. 
Human ZFP57 acts zygotically, with recessive mutations associated with the 
imprinting disorders TNDM and a specific pattern of MLID93, although this may 
represent ascertainment bias of mutation patterns that are compatible with life (Fig. 
4e). It is probable that additional KRAB ZFPs expressed in the oocyte, acting via 
maternal-effect, are involved in earlier imprinting centre maintenance in humans with 
a degree of redundancy between ZFPs in recruiting the KRAB repressor complex to 
specific gDMRs.  
Human mutations have rarely been identified in other zygotic factors implicated in 
methylation maintenance, presumably because complete ablation would be 
incompatible with life, as seen in mouse models (for example, Trim2894, Uhrf195 and 
Dnmt171). Nonetheless, haploinsufficiency of TRIM28/KAP1 has been associated 
with polyphenism, obesity and reduced expression of imprinted genes in mice and 
humans96, and haploinsufficiencies of DNMT1 and UHRF1 have been described in 
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association with BWS and MLID, respectively39,97. Cis-acting genetic variants have 
been identified in imprinting centre sequences, and study of these variants can help 
identify the zygotic factors that act on them to perpetuate the imprinted status (Fig. 
4f-g). Inherited microdeletions in IC1 (which controls the imprinted expression of 
IGF2 and H19 at chromosome 11p15.5) mostly derived from recombination between 
repeats have been described in individuals with BWS30 and SRS98, but interestingly 
their effects are seen only in maternal and paternal inheritance, respectively, and the 
methylation defects are generally mosaic, once again suggesting that imprinted 
states acquired in the early embryo are faithfully perpetuated in subsequent 
development. In patients with SRS, no maternal transmissions have yet been 
reported, but it is suggested that loss of ZFP57 binding sites may result in 
postzygotic attrition of methylation (Fig. 4f)29; in patients with BWS, erroneous GOM 
of the maternal allele is thought to result from loss of SOX2 and POU5F1 binding or 
weakening of CTCF binding28,99 (Fig. 4g). Murine models demonstrate that CTCF 
and ZFP57-binding sequences are involved in embryonic maintenance of IC1 
imprinting90,100, although some differences may exist between human and mouse 
species101.  
In summary, it seems that imprinting centre sequences have characteristics that 
support allele-specific gene expression, chromatin organization and DNA 
methylation in the early embryo, enabling these patterns to evade early-embryonic 
reprogramming and subsequently persist in somatic tissues. 
 
[H2] Intergenerational inheritance of imprinting defects 
Most imprinting disorders caused by epimutations occur in individuals with no 
relevant family history (primary epimutation). In such cases the underlying molecular 
cause may be associated with an environmental insult or stochastic error, and the 
risk of further cases in the family is minimal. Consistent with the hypothesis of non-
heritability of primary epimutations, a methylation defect shown to have originated in 
an individual with SRS was subsequently abolished in his germline (Fig. 5a)102. 
However, a subset of isolated cases may have an underlying genetic cause even in 
the absence of a family history (secondary epimutation). Multiple genetic causes of 
secondary epimutations have been identified, providing important information on the 
cis-acting elements and trans-acting factors involved in imprinting control. Often, 
these cases are autosomal dominantly inherited, with parent-of-origin effects on 
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penetrance, such that the epimutation and clinical phenotype only appear on 
maternal or paternal transmission (for example, familial PWS with paternally-
inherited imprinting centre mutations (Fig. 5b)46, and familial BWS associated with 
maternally-inherited IC1 microdeletions (Fig. 5c)30 and POU5F1-binding sites 
variants99). However, autosomal recessively inherited TNDM is caused by 
pathogenic variants in ZFP57 (Fig. 5d)93, and maternal pathogenic variants in 
maternal-effect genes (NLRP2, NLRP5, NLRP7, PADI6 and OOEP) (Fig. 5e)39 are 
associated with MLID in offspring. In the case of maternal-effect variants, the 
recurrence risk after an affected pregnancy can be up to 100% (recurrence may be 
avoided by oocyte donation), although even in the most severe forms penetrance 
may be incomplete (for example, NLRP7 familial hydatidiform moles) and there may 
be variable phenotypic expression37,39. 
Genetic variants associated with imprinting centre epimutations can demonstrate 
variable clinical presentation and incomplete penetrance28 or apparent anticipation 
[G] with increased clinical severity over multiple generations103. These findings 
suggest that whereas highly-penetrant variants, such as those disrupting 
transcription factor binding, exhibit patent and penetrant phenotypes, genomic 
variants with lower penetrance may need to be identified by comprehensive 
sequencing efforts. Consistent with this hypothesis, a recent study demonstrated that 
frequent sequence variants have subtle effects on imprinted methylation, expression 
and phenotype20, suggesting that imprinting is a more quantitative than categorical 
phenomenon. 
 
[H1] Environmental influences on imprinting 
In addition to genetic causes of imprinting centre epimutations, environmental factors 
may also influence the imprinting process. In humans, evidence for this phenomenon 
derives from assisted reproductive technologies (ART)104. Other environmental 
influences on imprinting centres may include nutritional status or exposure to 
chemical pollutants in utero105. In many cases, changes in methylation represent 
increased variability on the methylated allele, likely relating to a failure of 
maintenance, or an adaptive response to the external stimuli. 
 
[H2] Assisted reproductive technologies 
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ART is usually performed for male and/or female infertility and includes procedures 
such as ovarian hyperstimulation to obtain multiple oocytes for retrieval, in-vitro 
fertilization (IVF), intracytoplasmic sperm injection (ICSI) and embryo culture and 
transfer, all of which coincide with critical events in epigenome reprogramming. 
Reports of ART-conceived children with rare imprinting disorders (for example, AS 
and BWS) first suggested a potential link with the occurrence of epimutations at 
imprinting centres (Fig. 6)106-108. Epidemiological studies have provided further 
evidence for an increased risk of having children with BWS, AS or SRS when using 
ART104,109, although the absolute risk is very small (for example, for BWS up to 10-
fold increased risk compared to no ART, and <0.1% of all children conceived with 
ART help)109. ART has also been associated with an increased frequency of MLID, 
but this has not been a universal finding110,111. MLID and Large Offspring syndrome 
(a condition with similarities with BWS) have been observed in bovine fetuses 
conceived by IVF112. In pigs, global genomic DNA methylation and/or gene 
expression, including imprinted loci and genes involved in epigenetic 
reprogramming, were altered in blastocysts produced by IVF and partially restored 
with addition of natural reproductive fluids113. Furthermore, superovulation and 
embryo transfer induced developmental defects and imprinting centre epimutations 
in the placenta of mouse models114. 
In addition to ART-related procedures, infertility per se has been linked to the 
pathogenesis of imprinting disorders (Fig. 6). The frequency of AS with epimutations 
was shown to be increased in subfertile couples, independent of IVF, ICSI or embryo 
culture115. More recently, impaired methylation of imprinting centres was reported in 
sperm of subfertile men47. Furthermore, unrecognized ART-associated epigenetic 
alterations may play a role in the increased risk of low birthweight and congenital 
anomalies that have been reported in ART-conceived children116 and animal 
models117. Maternal age and delayed ovulation or fertilization are associated with 
depletion of oocyte proteins and RNA stores and altered developmental fitness of 
embryos118-120, suggesting that maternal effect genes may be critically vulnerable to 
these or other challenges that occur during ART (Fig. 6).  
Disentangling the effects of infertility and ART in the aetiology of ART-associated 
imprinting disorders in humans is difficult and not all studies have shown an 
association between ART and altered methylation, with some reports suggesting that 
there is no increase in mosaicism or methylation aberrations at imprinted 
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gDMRs121,122. Other groups have reported perturbed imprinting in pre-implantation 
embryos suitable for transfer123, suggesting that — similar to aneuploidy — 
epigenetic mosaicism in early embryos may be a normal occurrence. The rarity of 
ART-associated imprinting disorders suggests that they may result from a 
combination of multiple interacting factors, including specific aspects of ART 
protocols, infertility, genetic susceptibility and stochastic effects (Fig. 6). Moreover, 
epidemiological surveys often have ascertainment bias for liveborn offspring with 
clinically blatant phenotypes associated with imprinting disorders, while the 
frequency of clinical pregnancy, though well-known to be limited in ART, is not 
considered. Potentially, individuals with imprinting disorders represent the subset of 
IVF outcomes with the least pervasive disturbance and the most recognizable clinical 
features, and a more definitive study will require consideration of nonviable products 
of conception at all stages, including both epigenome and genome integrity. 
 
[H2] Nutrition and metabolic disorders 
Certain developmental windows are especially vulnerable to abnormal nutritional 
states124, including pre- and early post-implantation development and lineage 
segregation when epigenetic modifications are re-established. Recent studies have 
indicated that maternal metabolic disorders can have lasting effects on offspring 
through many pathways, which are beginning to be characterized (Fig. 6). Maternal 
dietary and genetic obesity have been shown to reduce Dppa3 expression in mouse 
oocytes; the resultant significant increase in 5hmC and concomitant reduction in 
5mC in maternal pronuclei produces subsequent hypomethylation at several 
imprinted gDMRs125.  
Nutritional status may also affect epigenetic profiles at imprinted loci in a variety of 
ways. It is possible that the availability of free methyl donors, such as S-
adenosylmethionine, a substrate for DNA and protein methylation, is limited, with 
evidence that methyl-deficient diets, folate levels and genetic variants in proteins 
involved in one-carbon metabolism all affect imprinted methylation patterns, at the 
11p15.5 imprinted gene cluster97,126,127. In these studies, the presence of missense 
amino acid substitutions in genes regulating the S-adenosyl methionine (SAM) or the 
inhibitory S-adenosylhomocyteine (SAH) abundance correlate with aberrant 
imprinted methylation126,127, which also revealed a link between low vitamin 
B12 levels and H19 methylation maintenance126 Functional genetic variants of 
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DNMT1 in BWS patients were also observed in combination with SNV of folate 
metabolism pathway genes, suggesting that decreased DNMT1 enzymatic activity 
could be exaggerated by extreme SAM/SAH ratios97. Furthermore, the ZFP57 locus 
is a folate-sensitive region, and its genomic binding regions are metastable epialleles 
responsive to periconceptional conditions128,129. In mouse, withdrawal of maternal 
dietary protein permanently altered imprinted expression of Cdkn1c in offspring, 
which was maintained into adulthood and occurred through a folate-dependent 
mechanism of DNA methylation loss130. However, not all studies on isocaloric protein 
restriction during pregnancy have resulted in altered imprinted methylation in the 
newborn131, suggesting that any deregulation is likely a consequence of a general 
effect on global methylation. Recent evidence suggests that cells have important 
energy status sensors that protect the cells against metabolic stress by directly 
regulating epigenetic processes. The nicotinamide adenine dinucleotide (NAD)-
dependent deacetylase, SIRT1 has been shown to protect methylation at imprinted 
loci by directly regulating acetylation of DNMT3L, at both the promoter and protein 
level in mouse embryonic stem cells132.  
 
Endocrine disruptors  
In addition to micronutrient availability, prenatal exposure to estrogenic endocrine-
disrupting compounds (EDC), such as bisphenol A (BPA), results in deregulation of 
genomic methylation and hydroxymethylation133,134, with imprinting and methylation 
anomalies being reported in both mouse placenta135 and developing gametes136,137. 
Endorsing the vulnerability of imprinted loci to EDCs, prenatal BPA exposure in 
humans has been associated with changes in methylation at the MEST locus and is 
linked with early childhood obesity138. Dnmt1 expression was found to be decreased 
in BPA-treated mouse spermatogonia137, and BPA exposure during oocyte 
maturation altered other epigenetic marks, specifically the abundance of histone 
modifications, which was linked to induced oxidative stress139. Exposure-induced 
oxidative stress was shown to alter both TET enzyme expression and function, 
leading to altered 5-hmC levels at numerous imprinted loci134, which indicates that 
environmental toxicants also alter long-term imprinted gene regulation (Fig. 6). 
Indirect effects of the toxic compounds on DNA methylation could also be exerted as 
consequence of developmental and metabolic alterations140.  
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In summary, combined genetic and environmental predispositions may erode the 
gametic and zygotic competence to reprogramme the epigenome, with 
consequences on imprint maintenance, and insights into these effects in humans 
may be gained by delineating the aetiology of apparently sporadic primary 
epimutations in individuals with imprinting disorders. 
 
[H1] Conclusions and perspectives  
The maintenance of differential DNA methylation of imprinting centres is fundamental 
for the survival of imprinting marks in the early embryo. Some of the key factors and 
genomic sequences involved in this process have been identified, but the causation 
and timing of their interactions require further clarification. This is particularly true for 
the SCMC proteins and possibly further oocyte-specific factors that affect DNA 
methylation maintenance in the early embryo, whose mechanisms of action and 
relationship with ZGA are still ill-defined. Importantly, further human-based studies 
are required, firstly to resolve key differences from mouse in the timing and 
mechanisms of epigenetic remodelling, and secondly to learn from rare cases of 
imprinting disorders by identifying genetic variants that predispose to imprinting 
centre epimutations. 
It has also become evident that environmental changes can affect the epigenetic 
reprogramming of germ cells and early embryo, altering their developmental 
competence and causing imprinting disorders. The availability or activity of factors 
needed for imprint establishment or maintenance may be affected by exposure to 
chemical pollutants, under- or over-nourishment, or other emergent factors. Omic 
and functional analyses of early embryos and nonviable reproductive outcomes will 
clarify the relationship between epigenomic and genomic integrity, uncover the key 
processes involved, and enable the creation of model systems in which primary 
imprinting centre epimutations can be created and explored. 
Cellular-physiological approaches are beginning to uncover key interactions of 
imprinted gene products, their effects on growth and metabolism, and their 
disturbance in imprinting disorders32-34,101. Such approaches, and their extension into 
human pathophysiology, will shed further light on molecular mechanisms of disease, 
(epi)genotype–phenotype correlations, phenotypic modification by mosaicism and 
MLID, and potential therapies for some of the resultant endocrine and growth 
disturbances. 
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More fundamentally, there are possibilities for therapeutic correction of imprinting 
disorders based on the reversal of gene imprinting status. Three therapeutic 
approaches for the neurological disorders AS and PWS have been proposed141-143. 
The AS/PWS locus contains a maternally methylated imprinting centre that directs 
the paternal expression of several genes, including a snoRNA cluster with a critical 
role in PWS and an antisense regulator (UBE3A-ATS) of the maternally-expressed 
E3 ubiquitin ligase UBE3A, the expression of which is lost in AS (Table 1). It was 
demonstrated that a topoisomerase inhibitor143 as well as antisense 
oligonucleotides141 are able to downregulate UBE3A-ATS and reactivate the paternal 
UBE3A in mouse models of AS, whereas G9a inhibitors can unsilence the maternal 
snoRNAs in a PWS model142. Another exciting approach is the direct modification of 
epigenetic marks at imprinted genes using catalytically inactivated Cas9 (dCas9) 
fusion proteins. Although still in their infancy, dCas9–DNA methyltransferase fusions 
have been able to target methylation to IC1 in mouse cells144, a promising 
technology if such alterations can be performed in an allelic fashion. Future 
experiments will demonstrate whether these approaches with small molecules may 
revert other epimutations in imprinting disorders and possibly be applied in other 
epigenetic-based human diseases. 
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Box 1 | Epigenetic mosaicism in imprinting disorders. 
Numerous patients with imprinting disorders, with or without MLID, have somatic 
mosaicism, in which tissues contains cells with imprinting aberrations as well as 
those with appropriate allelic methylation. Mosaicism is observed with all types of 
primary and secondary epimutations, with the exception of erasure and 
establishment errors (Fig. 4), indicating a more common post-zygotic aetiology36. In 
principle, the developmental period immediately prior to implantation, when the 
embryonic epigenome is reprogrammed, is particularly vulnerable. During this time, 
failure to selectively protect imprints may result in hypomethylation in individual cells 
and their progeny. If the event occurs late in pre-implantation development, after 
lineage commitment, tissue-specific epimutations may result. Conversely, failure to 
preserve imprints from the substantial remethylation that occurs post-implantation 
may give rise to mosaic hypermethylation; this may account for the IC1 
hypermethylation seen in BWS28,145, and imprinted gene-DMR hypermethylation in 
Kagami-Ogata syndrome146.  
Patients with SRS or BWS often present with body asymmetry, a feature accredited 
to mosaicism, with recent mouse models for these two imprinting disorders 
identifying mosaicism in bilateral organs with asymmetric growth100. Mosaic H19 
hypomethylation is common in SRS, for which severity differs markedly between 
patients147. Detailed studies in another imprinting disorder, Angelman Sydrome, 
explored the timing of such an event. In a female patient with mosaic SNURF 
hypomethylation, X-chromosome analysis showed that cells with the imprinting 
defect had either the paternally-derived or maternally-derived X chromosome 
inactivated, suggesting that the insult occurred before X-inactivation and 
implantation148. In principle, somatic imprinting errors may occur at any time in 
dividing cells. Immediately following replication, the methylation pattern on the 
template strand is recognized by the UHRF1-DNMT1 maintenance 
methyltransferase complex and copied onto the daughter strand. A failure to 
recognize or copy this pattern will result in a sustained hemimethylated profile that 
will segregate in subsequent cell divisions in a tissue-restricted manner.  
A phenomenon related to epigenetic mosaicism is represented by discordant 
monozygotic twins. Discordant monozygotic twins, whereby one twin has the 
disorder (nearly always female and often with MLID) and the other is healthy, are 
over-represented in patients with BWS36,37,39,149 and SRS150. suggesting that 
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monozygotic twinning is connected with epigenetic disturbances in early 
development. The occasional presence of mild clinical features of BWS and 
intermediate methylation disturbance in an unaffected twin151 supports the 
hypothesis that imprinting centre epimutations precede and possibly trigger the 
twinning process in the early embryo. 
 
 
Box 2 | Transient imprinting 
 A transient form of imprinting has been described in both mouse and human pre-
implantation embryos5,51,152 where DNA methylation is either lost on the maternal 
alleles or acquired by the paternal alleles post implantation. At the Gpr1/Zdbf2 locus, 
transient monoallelic expression of Gpr1-as1 mediates the accumulation of 
methylation at the Zdbf2 DMR, whose stable maintenance in adult somatic tissues 
regulates Zdbf2 allelic expression152. More recently, widespread transient imprinting 
derived from oocyte-specific methylation has been demonstrated in human 
placenta21. Epigenetic marks other than DNA methylation may also mediate transient 
imprinting, although this has not been reported in humans26. In mouse morula, some 
loci that display maternal allele-specific histone 3 lysine 27 trimethylation 
(H3K27me3) marks are expressed from their paternal alleles. This form of imprinted 
expression is largely lost later in development in the embryonic cell lineage but is 
retained at a few loci in extra-embryonic tissues. Further studies are needed to 
determine if this form of DNA methylation imprinting is conserved in other species 
and what its impact is on gene expression and phenotypes at later developmental 
stages. It is possible that transient and DNA methylation-independent monoallelic 
expression control the establishment of secondary gDMRs and consequently lead to 
a more stable imprinted expression in somatic tissues. 
 
Box 3 | Zygotic genome activation 
Epigenetic reprogramming and zygotic genome activation (ZGA) are intimately linked 
in the early embryo (see the figure; maternal (red line), early zygotic (blue line) and 
embryonic (black line) transcripts are shown). Approximate timing (days) of human 
cleavage-stage divisions and blastulation are shown. Upon maturation, the oocyte 
ceases transcription and translation, which do not resume in human embryo until 
around the 8-cell stage; therefore, the early embryo relies substantially on maternally 
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provided oocyte protein and RNA. From the time of fertilization, maternal RNA is 
progressively degraded. The paternal genome supports an early wave of 
transcription (see the figure; blue line) that is essential for major ZGA153.  
In the 1-cell embryo, the maternally-derived histones that replace sperm protamines 
do not at first establish the patterns of euchromatin and heterochromatin normally 
seen in somatic cells, and as a result, chromatin on the paternal genome remains 
atypically accessible. The paternal genome supports low-level transcription of 
sequences normally repressed within heterochromatin, such as retroviral repeats, 
and pioneer factors like DUX4154. Pioneer factors support transcription of cleavage-
stage transcription factors that trigger major ZGA. Upon ZGA the genome attains a 
more somatic organisation, blocking the return to the permissive, early pattern of 
transcription. 
 
Fig. 1 | The imprinted 11p15.5 region as an example of epigenetic error in 
imprinting disorders. a | Model of the 11p15.5 region represented as alternative 
chromatin loops on the maternal and paternal chromosomes. The model is based on 
the results of chromatin conformation capture studies in human cells22,23. Loops 
anchors occur at CTCF-cohesin binding sites. On the maternal chromosome (red 
line), a loop is formed between a distal region (HIDAD) located at 1.72 Mb and the 
unmethylated IC1. On the paternal chromosome (blue line), the formation of this loop 
is prevented by IC1 methylation and an alternative one is formed between HIDAD 
and the IGF2 promoter. Alternative loops may facilitate differential activation of H19 
and IGF2 by common enhancers on the maternal and paternal chromosomes, 
respectively155. b | Chromosome interactions and gene expression changes 
predicted by the looping model as consequence of IC1 LOM in SRS155. H19 is 
activated and IGF2 silenced on both parental chromosomes. c | Chromosome 
interactions and gene expression changes predicted by the looping model as 
consequence of IC1 GOM in BWS155. H19 is silenced and IGF2 activated on both 
parental chromosomes. Chromosome distances are not in scale. 
 
Fig. 2 | Chromosome 11p15.5 — an example of an imprinted gene cluster. 
Within the telomeric domain, enhancers (green ovals) direct transcription of the long 
non-coding RNA (lncRNA) H19 and the intragenic microRNA (miRNA) miR-675 on 
the maternal chromosome (red line) and that of the growth factor gene IGF2 and the 
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intragenic miR-483 on the paternal chromosome (blue line). The imprinting centre 
(IC) of the telomeric domain (IC1; inset panel), also known as H19/IGF2 intergenic  
differentially methylated region (DMR), contains tandem repeats (light red and blue 
rectangles) and is bound by the transcription factors (TFs) CTCF, POU5F1 and 
SOX2, which maintain the unmethylated status of the maternal allele, whereas 
ZFP57 maintains the methylated status of the paternal allele. IC1 and IC2 are also 
characterized by different chromatin configurations on parental chromosomes, with 
repressive histone marks, such as H3K9me2, H3K9me3 and H4K20me3 on the 
methylated allele, and permissive histone marks, such as H3K4me2 and H3K4me3, 
on the unmethylated allele. Secondary DMRs (H19 promoter (prom), IGF2 DMR0 
and IGF2 DMR2) are paternally methylated. The imprinting centre of the centromeric 
domain (IC2), also known as KCNQ1OT1:TSS–DMR, is maternally methylated and 
directs maternal-specific expression of KCNQ1 and the cell cycle regulator CDKN1C. 
On the paternal allele, a lncRNA intragenic to KCNQ1 (KCNQ1OT1) is transcribed 
(wavy blue lines), suppressing in cis the expression of coding genes in the region. 
IC2 methylation and silencing of the KCNQ1OT1 promoter are maintained through 
interaction with ZFP57 on the maternal chromosome, while as yet uncharacterized 
TFs sustain KCNQ1OT1 transcription on the paternal allele. Active alleles are 




Fig. 3 | The life cycle of imprints. DNA methylation reprogramming during human 
development. Methylation of imprinting centres (dashed black line) is erased more 
slowly than that of the rest of the genome (black line) in PGCs and re-established 
with different kinetics in male (paternal imprinting centres, dashed blue line; whole 
genome, blue line) and female (maternal imprinting centres, dashed red line; whole 
genome, red line) germ cells. After fertilization, the maternally and paternally derived 
genomes are widely demethylated, while differential methylation between maternal 
and paternal imprinting centre alleles (50% level) is maintained pre- and post-
implantation. Factors and events involved in each stage, 5mC level and approximate 
timing of imprint erasure, establishment and pre/post-implantation maintenance are 
indicated. GVs, germinal vesicles. 
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Fig. 4 | Mechanisms of imprinting errors in human diseases. In each panel, 
normal mechanisms are on the left, defective mechanisms on the right. a | Defective 
IC methylation erasure in PGCs. b | Defective transcription (dashed red arrow) 
across imprinting centre and imprint establishment in oocyte. c | Defective oocyte 
factor (striked pink triangle) impacting imprint establishment in oocyte. d | Defective 
oocyte factor (striked pink diamond) impacting developmental competence and 
imprint maintenance in pre-implantation embryo. e | Defective zygotic factor (white 
asterisk) and imprint maintenance in pre-implantation embryo. f | Defective target 
site (indicated with x) for transcription factor protecting methylated imprinting centre 
and imprint maintenance in pre-implantation embryo. g | Defective target site for 
transcription factor recognizing unmethylated imprinting centre and imprint 
maintenance in post-implantation embryo. Methylated and unmethylated imprinting 
centres: black / white lollipops. Mosaic methylation is indicated by grey lollipops. 
MLID is indicated by LOM at multiple imprinting centres. Maternally methylated 
imprinting centres are in red, paternally methylated imprinting centres in blue. Trans-
acting factors are as in Fig. 1. 
 
Fig. 5 | Modes of inheritance of phenotypes associated with imprinting errors.  
a | Pedigree of sporadic SRS case in which IC1 epimutation is corrected in the 
germline of the proband. Black lollipop shows normal full methylation of paternal IC1 
in blood of I:1 and in the sperm of II:1; grey lollipop, mosaic hypomethylation of 
paternal IC1 in blood of II:1; b-c | Pedigrees showing autosomal dominant 
inheritance with parent-of-origin-dependent penetrance (paternal, associated with 
PWS/AS imprinting centre mutation in b; maternal, associated with BWS/SRS IC1 
mutation in c; d | Autosomal recessive (ZFP57 mutation); e | Maternal effect (NLRP5 
mutations). Colored symbols indicate: SRS cases, purple; PWS cases, brown; BWS 
cases, blue; TNDM cases, green.  
 
Fig. 6 | Interaction between environmental and genetic factors and its impact 
on genomic imprinting. The diagram summarizes the evidences obtained in 
humans and animal models of interaction of environmental factors and physio-
pathological conditions (depicted in light blue) with gametic and zygotic factors 
(yellow) involved in de novo and maintenance methylation and impacting imprinting 
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establishment and maintenance (pink). Continuous lines indicate functional 
contribution; dashed lines, functional interference. 
 











1/300.000 Chr 6q24  
 
- upd(6)pat (41%).  
- Paternal duplications (29%).  
- PLAGL1:alt-TSS-DMR LOM 
(30%) (MLID: 30% caused by 







abdominal wall defects 
Silver-Russell 











- upd(7)mat (5–10% (MLID: 
rare161))  
- upd(11p15)mat (rare) 
- 11p15 CNVs (<1%) 
- H19/IGF2:IG:DMR LOM (30-
60% (MLID: 7–10% 37,39,147)) 
- CDKN1C, IGF2, 
HMGA2, PLAG1 point 
mutations (rare) 
IUGR, PNGR, relative 

















1/15.000 Chr 11p15  
 
- upd(11p15)pat (20%) 
- 11p15 CNVs (2–4%) 
- H19/IGF2:IG:DMR GOMa 
(5%) 
- KCNQ1OT1:TSS-DMR LOM 
(50% (MLID: 25%37,39)) 
- CDKN1C point mutations (5% 
















unknown Chr 14q32 - upd(14)pat (65%) 
- 14q32 maternal deletion 
(20%) 
- MEG3/DLK1:IG-DMR GOM 
(15%) 
IUGR, polyhydramnion, 
abdominal wall defects, 
bell-shaped thorax, 
coat-hanger ribs 




- 14q32 paternal deletion (10%) 
- MEG3/DLK1:IG-DMR LOM 
(61%) 
neonatal hypotonia, 
feeding difficulties in 
infancy, truncal obesity, 
scoliosis, precocious 










- 15q11–q13 paternal deletion 
(75-80%) 
- Upd(15)mat (20-25%) 
- SNURF:TSS-DMR GOMa 














- Maternal deletion (70-75%) 
- Upd(15)pat (3-7%) 
- SNURF:TSS-DMR LOMa (2-
3% (MLID: rare172)) 
- UBE3A point mutations (10%) 
Severe intellectual 
disability, microcephaly, 




puberty 2 (CPPB2) 
175  
615356 
Unknown Chr 15q11.2  - MKRN3 point mutations 
(100%) 
Early activation of the 
hypothalamic–pituitary–





syndrome (SYS)176  
615547 












Unknown Chr 20q13:  - GNAS inactivating variants of 
the maternal allele (100%) 

















Unknown Chr 20q13  - 20q13 maternal deletion 
(8.5%) 
- GNAS DMRs LOM (42.5%; 
MLID: 12.5%178,179) 
- upd(20)pat (2.5%) 
- 20q13 point mutations (46.5%) 















Unknown Chr 20q13 - GNAS inactivating variants of 
the paternal allele (100%) 
Mild resistance to PTH 
and other hormones, 
subcutaneous 
ossifications, birth 








Unknown Chr 20q13 - GNAS inactivating variants of 






Unknown Chr 20 - upd(20)mat (100%) IUGR, PNGR, feeding 
difficulties 
a Imprinting defects can either be due to primary imprinting epimutations without DNA sequence alterations, or 
due to deletions in the imprinting center (IC) critical regions. GOM, gain of methylation; IUGR, intrauterine growth 
restriction; LOM, loss of methylation; PNGR, postnatal growth restriction; PTH, parathyroid hormone; UPD, 
uniparental disomy. 
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aThese imprinted DMRs show evidence for mosaicism in the general population with low frequency 
hypomethylation reported. bThe entire ~1MB interval between the NDN and SNURF DMRs (chr15:24112253-
25108042) is preferentially methylated on the maternal allele. cTranscription factor binding sites taken from: YY1 
ChIP-seq ENCODE datasets (March 2012); CTCF ChIP-seq ENCODE datasets (March 2012); ZFP57 ChIP-seq 
dataset Imbeault et al., 2017. Nature 543:550-554; POU5F1 ChIP-seq ENCODE datasets (March 2012). HGVS, 
Human Genome Variation Society; M, maternal; P, paternal. 
 
Table 3. Factors with potential roles in imprinting control. 





Possible role in active 
demethylation in 
PGCs 
Modest global hypermethylation 
in deficient PGCs182 
not reported  
TET1 and TET2 Implicated in 
demethylation as they 
have specific activity 
for converting 5mC to 
5hmC 
DKO mice have reduced 5hmC 
and increased 5mC levels at 
some imprinted loci (Mest, Peg3, 
Igf2r, H19)45 
not reported 
DNMT3A/B De novo DNA 
methyltransferase 
No methylation at gDMRs183 not reported 
DNMT3L Associate factor for 
DNMT3 
No methylation at gDMRs53 No pathogenic variants 
identified in SRS184 
KDM1B Oocyte-specific H3K4 
demethylase 
LOM at multiple gDMRs (Mest, 
Grb10, Zac1, Impact, U2af1-rs1, 
Peg10, Nnat, KvDMR1, Igf2r, 
Gnas)60,62 
not reported 
KDM1A H3K4 demethylase LOM at transient Cdh15 gDMRs 
62 
not reported 
NLRP7 NACHT, LRR and 
PYD domains-
containing protein 7 
potentially a SCMC 
interacting proteins 
No mouse orthologue Biparental hydatidiform moles 
with complete lack of maternal 








Widespread LOM during 
embryonic cleavage stages187,188 
BWS with IC2 LOM97 
 
DNMT3A/B De novo DNA 
methyltransferase 
No methylation at gDMRs54,183 not reported 
ZFP57 KAP1 recruiting zinc-
finger protein 
Widespread LOM during 
embryonic cleavage stages87 
TNDM patients with MLID93 
TRIM28/KAP1 KRAB1-associated 
protein repressor 
Partial LOM during embryonic 
cleavage stages (H19, Snrpn)94 
No pathogenic variants 
identified in MLID36 
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complex  
UHRF1 Guides DNMT1 to 
hemimethylated DNA 
during replication 
Partial LOM during embryonic 
cleavage stages (H19, KvDMR1, 
Ig-DMR)95 
Single case of MLID39 
Histone H1 Linker histones Triple KOs result in Partial LOM 
(H19, Ig-DMR) 
not reported 
MBD3 Methyl-CpG binding 
protein 
Partial LOM at H19189 No pathogenic variants 
identified in SRS184 
MTA2 Metastasis tumour 
antigen 2, member of 
NuRD complex 





LOM at Snrpn in double KOs191 not reported 
DPPA3/STELLA Binds to methylated 
and H3K9 decorated 
gDMRs 
Partial LOM at several gDMRs 
(Snrpn, Mest, Peg3, Nnat, 
Peg10, H19, Rasgrf1)74 
No pathogenic variants 
identified in MLID147 
 
NLRP2 NACHT, LRR and 
PYD domains-
containing protein 2 
potentially a SCMC 
member 
Aberrant gDMRs (GOM and 










Imprinting not assessed84 Biparental hydatidiform moles. 
LOM at several DMRs 
(KvDMR1, SNRPN, MEST, 
PEG3, GNAS XL, GNAS 
A/B)76,192 
No pathogenic variants 
identified in MLID36,186 
NLRP5/MATER Member of SCMC Imprinting not assessed82 MLID37 
OOEP Member of SCMC Imprinting not assessed193 Single case of MLID39 
PADI6 Member of SCMC Imprinting not assessed83 MLID39 
ZAR1 Oocyte-specific zinc 
finger protein  
Imprinting not assessed194 Single case of MLID39 
VEZF1 Zinc finger 
transcription factor 
DB1 
Partial LOM at H19 and Igf2r 
gDMRs195 








LOM of secondary DMRs in 




Aberrant gDMRs (GOM and 
LOM)197 
not reported 




partial LOM at H19199 
CTCF Zinc finger protein 
involved in chromatin 
organisation 
GOM at H19200 Microdeletions of CTCF binding 
sites result in IC1 GOM in 
BWS28,201,202 
ZFP42/REX1 Zinc finger protein GOM at Peg3 and GNAS203 not reported 
POU5F1 Pioneer pluripotency 
transcription factor 
Imprinting not assessed204  Binding site pathogenic variants 
leads to IC1 GOM in 
BWS99,205,206 
SOX2 Pioneer pluripotency 
transcription factor 
Imprinting not assessed207  Binding site pathogenic variants 
leads to IC1 GOM in 
BWS99,103,205,206 





Genomic imprinting  
The epigenetic marking of a gene on the basis of parental origin, which results in 
monoallelic expression.  
 
Anticipation 
A phenomenon whereby the symptoms of a genetic disorder become apparent at an 
earlier age or with greater severity in succeeding generations. 
 
Assisted reproductive technologies 
(ART). Techniques used to achieve pregnancy during the treatment of infertility. ART 
covers a wide spectrum of treatments including the use of fertility drugs, intrauterine 
insemination and in vitro fertilization/intracytoplasmic sperm injection. 
 
Blastocyst  
Developmental stage of mammalian embryo just before implantation consisting of an 
inner cell mass which will form the embryo, and a cavity with an outer layer called 
trophoblast, which will give rise to the placenta. 
 
cis-acting element  
DNA sequence regulating the expression of a gene that is present on the same 
chromosome. 
 
Copy number variation 
(CNV). Type of structural variation of a chromosome consisting in duplication or 
deletion of DNA sequence. 
 
Endogenous retrovirus 
Repetitive genetic element present in the genome that, similarly to retroviruses, uses 









Chromatin modifications influencing genome function and not involving the 
underlying DNA sequence that can be propagated through cell division. 
 
Epigenetic reprogramming  




When referred to imprinting disorders, epigenetic change that affects the regulation 
of imprinted loci. The epimutation is primary if there is no detectable genetic cause, 
secondary if it is associated with a genetic cause. 
 
Imprinting disorders  
Diseases associated with disruption of imprinted gene expression that can be 
caused by genetic or epigenetic defects. 
 
Incomplete penetrance 
A situation in which not all individuals carrying a dominant deleterious genetic variant 
express the associated clinical phenotype. 
 
Gain of methylation 
(GOM). When referred to imprinting disorders, gain of methylation on the 
unmethylated allele of imprinting centre. It is detected in patients and causes 
deregulation of the imprinted genes in the domain controlled by the imprinting centre. 
  
Genome activation  
The initiation of gene expression in the developing embryo. The initial burst of 
expression is termed zygotic genome activation (ZGA) and is regulated by pioneer 
transcription factors during the oocyte-to-embryo transition. Initiation of expression in 
cleavage embryos is referred to as embryonic genome activation. 
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Germline differentially methylated region 
(gDMR): Regions of differential DNA methylation between parental alleles in somatic 
cells that originate from the gametes. gDMRs that survive embryonic reprogramming 
are generally associated with imprinted genes. 
 
Haploinsufficiency 
A situation in which half of the normal level of a gene product, usually consequence 
of a loss-of-function mutation, is not sufficient for the normal function. 
 
Hydatidiform mole 
Benign gestational trophoblastic disease developing during pregnancy and resulting 
from an abnormal fertilization. It is characterized by trophoblastic proliferation and 
little or no embryonic tissue. It is commonly sporadic and contains only sperm DNA. 
Occasionally, it can be biparental, recurrent and familial following an autosomal 
recessive mode of inheritance. 
 
Imprinting centre 
A function definition for gDMRs that have been shown to regulate imprinted genes 
expression through either genetic targeting in mouse or through mutations in 
patients. Also known as imprinting control region (ICR). Not all gDMRs have been 
shown to be imprinting centre regions. 
 
Loss of methylation 
(LOM). When referred to imprinting disorders, loss of differential imprinting centre 
methylation detected in patients and causing deregulation of the imprinted genes in 
the domain controlled by the imprinting centre. 
  
Multi-locus imprinting disturbance 
(MLID). Methylation anomalies at imprinted DMRs in patients with imprinting 
disorders in addition to those that are normally associated with the disease. 
 
Maternal effect gene 
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A gene coding for an oocyte-derived transcript or protein that is required for the early 
development of the embryo. 
 
Penetrance 
Proportion of individuals in a population with a specific genotype who show an 
associated phenotypic trait. 
 
Primordial germ cells 
(PGCs). Stem cell-like cells found in the gonadal ridge of developing embryos that 
develop into gametes following sex-specific epigenetic reprogramming and meiosis. 
 
Pronucleus 




Basic proteins that largely replace histones in the nucleus of mature sperm for more 
condensed DNA packaging. 
 
Secondary differentially methylated region 
A region of differential DNA methylation between parental alleles that does not 
originate from the germline. They are often referred to as somatic DMRs and are 
regulated in a hierarchical fashion by a nearby imprinting centre region. 
 
Subcortical maternal complex 
(SCMC). A large multi-protein complex comprising of NLRP5, OOEP, TLE6, PADI6 
and KHDC3L that localises to the outermost regions of the cytoplasm in oocytes and 
excluded from regions of cell-to-cell contact in cleavage embryos. 
 
trans-acting factor  




(UPD). Genetic defect characterized by the presence of two copies of a chromosome 
or part of it derived from only one parent. 
 
Zygote  
A fertilized ovum before the first cell division which represents the earliest stage of 
embryonic development. The zygote's genome is a combination of the DNA in each 
gamete. 
 
